EDDING GENOR (06998.HK): GB268 Wins NMPA Nod for NSCLC, BTC Trials
NewTimeSpace News: On 16 November 2026, Edding Genor Group Holdings Limited (stock code: 6998) announced that the IND for a Phase Ib/II clinical trial of GB268, its highly differentiated PD-1/CTLA-4/VEGF trispecific antibody, as monotherapy or in combination for metastatic (stage IV) non-small cell lung cancer (NSCLC), and the IND for a Phase II/III trial of GB268 with chemotherapy as first-line treatment for locally advanced or metastatic biliary tract cancer (BTC) not amenable to curative surgical resection, were approved by the China National Medical Products Administration (NMPA) on 12 November 2026.
The Company said the two milestones show preliminary regulatory recognition of GB268's clinical development plan and further deepen its multi-tumour portfolio. By finely tuning the activity of its PD-1, CTLA-4 and VEGF arms, GB268 improves the tumour immune microenvironment, promotes T-cell infiltration and exerts anti-angiogenic effects, showing potential to break the immune-resistance barrier in metastatic NSCLC; combined with chemotherapy in advanced BTC, it is expected to raise objective response rates, deliver deep and durable tumour shrinkage and prolong overall survival.
GB268 received its first-in-human clinical trial approval from the NMPA in July 2025, and preliminary Phase I monotherapy data showed good tolerability across the full dose range in previously treated patients with advanced solid tumours, with broad early efficacy signals across tumour types; the data were presented at the ESMO Congress in October 2026. It was cleared for a Phase Ib/II trial in locally advanced unresectable or metastatic breast cancer, including TNBC and HR+/HER2- disease, in June 2026, and for a Phase II trial with chemotherapy as first-line treatment of advanced colorectal cancer in October 2026.
- EDDING GENOR (06998.HK): GB268 Colorectal Cancer Phase II IND Approved
- EDDING GENOR (06998.HK): First subject dosed in Phase Ib/II trial of trispecific antibody GB268 for breast cancer
- Lingjie Aviation: closes RMB 10 million-level angel round solely funded by Shanghai Huxiang Investment, targeting eVTOL trading and capacity services
- HK Stock Connect Insight | JS GLOBAL LIFESTYLE (01691.HK) Rebounds Over 13% Since Removal; Controlling Shareholder Plans to Pledge 52.87% Stake on October 16
- YZYBIO-B (02496.HK): Proposes Issuing 35.59 Million Domestic Shares to Three Directors at RMB 2.43 Each, Raising about RMB 83 Million; Whitewash Waiver Sought and Trading to Resume